Vince & Associates Clinical Research has been awarded a contract with the FDA, Center for Drug Evaluation and Research (CDER), to conduct bioequivalence studies of innovator and generic drugs such as anti-epileptic drugs. The five-year contract has a maximum value of $5 million. Vince & Associates will conduct the studies and provide services including study design, protocol development and patient recruitment.   “With this contract we will seek to investigate the bioequivalence of gener...